Renishaw plc (RSW.L) Bundle
Founded in 1973 in Wotton-under-Edge to solve jet-engine measurement challenges, Renishaw plc has grown from an early milestone of £1.1m revenue in 1981 into a diversified precision-engineering and medical-technology group reporting a record £713.0m for the year to 30 June 2025; the company-still shaped by co‑founders Sir David McMurtry and John Deer after a halted process to sell their combined 53% stake in 2021-now spans Manufacturing Technologies and Analytical Instruments & Medical Devices, leads global CMM probe markets with around a 22% revenue share in 2024, and continues to push innovation with products such as the 2024 RenAM 500 Ultra featuring TEMPUS™ technology that can cut build times by up to 50%, while targeting high single‑digit revenue growth through the cycle and operating margins above 20% via R&D investment, global manufacturing and a direct-plus-distributor sales model.
Renishaw plc (RSW.L): Intro
Renishaw plc (RSW.L) is a UK-listed precision engineering and metrology company founded in 1973 in Wotton-under-Edge, England. It designs and manufactures precision measurement, motion control, additive manufacturing and healthcare technologies for industrial and medical markets worldwide.- Founders: Sir David McMurtry and John Deer (1973)
- Headquarters: Wotton-under-Edge, Gloucestershire, England
- Listing: London Stock Exchange (ticker RSW.L)
- Employees: ~5,000 (global, approximate)
| Fiscal year end | Revenue (£m) | Notable milestones |
|---|---|---|
| 1981 | 1.1 | First major revenue milestone - emergence in precision engineering |
| 1990 | - | Expanded product portfolio to include CMM probes (metrology) |
| 2000 | - | Entered medical devices market with neuromate® stereotactic robot |
| 2024 | - | Launched RenAM 500 Ultra additive manufacturing system with TEMPUS™ |
| 2025 (FY ended 30 Jun 2025) | 713.0 | Record revenue reported |
- 1973: Founded to solve precision measurement needs in jet engine manufacture.
- 1981: Achieved £1.1m revenue, establishing commercial traction.
- 1990s: Grew metrology range-coordinate measuring machine (CMM) probes and machine tool sensors-becoming a core supplier to automotive and aerospace OEMs.
- 2000s: Diversified into medical robotics and devices; launched neuromate® for neurosurgery.
- 2010s-2020s: Expanded additive manufacturing (metal powder bed fusion), spectroscopy, and medical dental markets; continued R&D-led product launches.
- 2024: Released RenAM 500 Ultra with TEMPUS™ technology, claiming up to 50% reduction in build times for industrial metal AM.
- 2025: Reported record FY revenue of £713.0m (year ended 30 June 2025), demonstrating resilience through market cycles.
- Public company structure: shares traded on the LSE (RSW.L).
- Founders historically significant: Sir David McMurtry (co-founder) retained a material shareholding and influence; executive and non-executive board oversee strategy and governance.
- Institutional holders and retail investors: typical mix for a UK mid/large-cap engineering group.
- Mission: Deliver precision measurement, process control and healthcare technologies that improve manufacturing quality, productivity and clinical outcomes.
- Strategic pillars:
- High-value metrology solutions for aerospace, automotive and electronics.
- Additive manufacturing for metal parts and production-scale AM systems.
- Medical devices and robotics focused on clinical accuracy and safety.
- Continuous R&D investment to maintain technology leadership.
- Metrology and inspection:
- Probe systems for CMMs and CNC machine tools (contact and non-contact probes, touch-trigger and scanning probes).
- Calibration and laser interferometry systems for high-precision measurement and machine tool verification.
- Additive manufacturing (AM):
- Metal powder bed fusion systems (RenAM series), process monitoring and powder handling systems.
- RenAM 500 Ultra with TEMPUS™ - industrial throughput improvements (up to 50% faster builds claimed).
- Healthcare:
- Neuromate® stereotactic robot and other surgical planning/positioning devices.
- Dental CAD/CAM and spectroscopy-based diagnostic tools in selective areas.
- Spectroscopy and Raman analyzers used in scientific and industrial applications.
- Product sales: capital equipment (CMM probes, AM machines, surgical robots) form a substantial portion of revenue and are higher-margin when paired with aftermarket services.
- Aftermarket and consumables: probes, styluses, calibration artefacts, AM powders, spare parts and upgrades provide recurring revenue and higher margin stability.
- Service, installation and training: commissioning, maintenance contracts and application support for industrial and medical customers.
- Software and automation: proprietary control and analytics packages for metrology and AM workflows.
- R&D and IP licensing: protected intellectual property underpins product differentiation and can generate licensing income.
| Metric | Value / Note |
|---|---|
| Revenue (FY ended 30 Jun 2025) | £713.0 million (record) |
| Key growth drivers | Recovery in industrial capital spending, AM system uptake, aftermarket sales |
| R&D intensity | Significant - ongoing product development across metrology, AM and healthcare |
| Geographic reach | Global sales and service network across Europe, Americas, Asia-Pacific |
| Employees (approx.) | ~5,000 worldwide |
- RenAM 500 Ultra (2024) - TEMPUS™ thermal/process control architecture, up to 50% reduction in build times claimed; targets production metal AM market.
- Continued enhancement of probe systems and machine tool rails for higher-speed, higher-accuracy measurement in factory environments.
- Further iterations of medical robotics and clinical systems expanding addressable healthcare applications.
- Revenue visibility benefits from aftermarket and service contracts that smooth capital equipment cyclicality.
- Competitive advantages: entrenched OEM relationships in automotive/aerospace, deep IP in metrology, and cross-selling between measurement and AM offerings.
- Risks: cyclical capital expenditure patterns, competition in AM and metrology, and sensitivity to exchange rates and component supply chains.
Renishaw plc (RSW.L): History
Renishaw plc was founded in 1973 by Sir David McMurtry and John Deer. The company grew from an engineering start-up into a global precision metrology, spectroscopy and additive manufacturing group, listed on the London Stock Exchange under the ticker RSW.- Founded: 1973
- Primary businesses: metrology (CMM probe systems, machine tool probing), Raman spectroscopy, additive manufacturing (metal powder bed fusion), encoder systems and dental CAD/CAM products
- Headquarters: Wotton-under-Edge, Gloucestershire, UK
- 2021: Sir David McMurtry and John Deer announced intention to sell their combined c.53% stake and initiated a formal sale process.
- July 2021: The sale process was terminated after the board concluded bids did not meet objectives; McMurtry and Deer retained their combined c.53% stake and continued to exert substantial influence.
- Post-2021-2025: The founders have reduced their holdings; by 2025 the shareholder base is materially more diversified, with a mix of institutional investors, retail shareholders and insiders.
| Year / Point | Event | Approx. Founder Holding |
|---|---|---|
| 2021 (pre-sale) | McMurtry & Deer announced sale of combined stake | c.53% |
| July 2021 | Sale process terminated; founders retained stake | c.53% |
| 2024 | Gradual reduction in founder holdings begins (ongoing share disposals/estate planning) | reduced versus 2021 (variable) |
| 2025 (current) | More diversified share register: institutions, individuals, insiders | founders' combined holding reported reduced (estimated c.30-36%) |
- Large founder stake historically concentrated strategic control and board influence.
- Post-2021 diversification increases influence of institutional investors and market scrutiny.
- Insider holdings (executives/directors) remain meaningful for alignment of management and long-term strategy.
Renishaw plc (RSW.L): Ownership Structure
Renishaw plc (RSW.L) is a UK-based engineering and scientific technology company focused on precision measurement, metrology, additive manufacturing and healthcare (notably neurosurgical products). Its strategic direction is driven by a clear mission and a set of core values that underpin product development, customer engagement and corporate stewardship. Mission and Values- Mission: To provide innovative solutions in precision measurement and healthcare that enhance productivity, accuracy and quality for customers across manufacturing and medical markets.
- Integrity: The company emphasizes ethical business conduct, regulatory compliance and transparency in reporting and governance.
- Sustainability: Renishaw has implemented energy-efficiency programs, waste reduction initiatives and targets to reduce environmental impact in its facilities and supply chain.
- Innovation: Substantial investment in R&D drives continuous product development-particularly in metrology probes, additive manufacturing systems and neurosurgical devices.
- Customer-centricity: Renishaw designs tailored solutions and provides application support to meet specific customer needs, focusing on uptime, precision and lifecycle value.
- Collaboration: The company fosters cross-functional teamwork, partnerships with OEMs, universities and research centres, and open communication internally and externally.
- Primary revenue streams: metrology products (probes, machine tool measurement), additive manufacturing (metal 3D printers and powder handling), healthcare (neurosurgical navigation and related devices), and aftermarket service/spares.
- Recurring revenue: service, calibration, spare parts and software upgrades provide higher-margin, recurring income alongside capital equipment sales.
- R&D-driven product pipeline: a significant portion of revenue is reinvested into R&D to maintain technological leadership in precision systems and medical devices.
| Metric | Value (most recent reported year) |
|---|---|
| Reported revenue | £333.9m |
| Operating profit (approx.) | £35.2m |
| Profit before tax | £21.7m |
| Net cash / (debt) | £193.0m |
| R&D spend | £75.6m (≈22.6% of revenue) |
| Dividend per share | £0.30 |
- Founder and executive ownership: The founding shareholders retain a controlling position-significant stakes are held by founder-related entities. As of the latest registry, Sir David McMurtry is the largest individual shareholder with ~37% and co-founder John Deer holds ~24.5%, giving founder-related parties a combined majority stake (~61.5%).
- Institutional investors: The balance of the free float is held by UK and international institutional investors, pension funds and retail holders. Institutional ownership provides liquidity on the London Stock Exchange (ticker RSW).
- Free float and governance impact: The concentrated ownership enables long-term strategic decision-making but also means founder views strongly influence capital allocation, dividend policy and corporate strategy.
- Long-term investment horizon: Founder control supports sustained R&D investment and conservative balance-sheet management, preserving cash buffers for product development and M&A opportunities.
- Dividend and returns policy: Renishaw has historically balanced returning cash to shareholders with reinvesting for growth-dividends are determined alongside cash generation and strategic investment needs.
- Governance: Strong founder presence is matched with a board and audit/remuneration committees intended to maintain governance standards and stakeholder transparency.
Renishaw plc (RSW.L): Mission and Values
Renishaw plc (RSW.L) develops, manufactures and sells precision measurement and healthcare products worldwide. The company's stated mission emphasizes precision engineering, innovation and improving outcomes in manufacturing and healthcare through accurate measurement, process control and minimally invasive surgical solutions. Core values include engineering excellence, continual R&D investment, customer partnership and long‑term thinking. How it works - business structure and operations Renishaw operates through two principal divisions:- Manufacturing Technologies: precision metrology products (CMM probes, touch probes, machine tool probing systems, equator gauging systems, machine calibration tools, additive manufacturing systems and related software). Key end markets: aerospace, automotive, semiconductor, general engineering and precision manufacturing.
- Analytical Instruments & Medical Devices: Raman spectroscopy instruments, process monitoring and biomedical/medical devices (including neurosurgical robotics and dental CAD/CAM workflow components). Key end markets: pharmaceuticals, academia/research, clinical diagnostics and specialist surgery.
- Direct sales force in major markets (first‑party customers and OEMs) supported by a global distributor network covering territories where direct presence is limited.
- After‑sales services: calibration, training, retrofit/spare parts and software upgrades provide recurring revenue and strengthen customer lock‑in.
- Vertical integration in key manufacturing/process areas while leveraging specialist partners and distributors to extend reach.
- Manufacturing sites: UK (several engineering and production sites), Ireland, India and Brazil.
- R&D and innovation centres: main research facilities in the UK and Ireland, with additional R&D presence in Slovenia and other locations for specialised development.
- Global sales & service network spans more than 70 countries via direct offices and authorised distributors.
- Renishaw is R&D‑led: a substantial portion of revenue is reinvested into product development. In recent reported years R&D investment has been in the tens of millions of pounds annually (typically mid‑teens percentage of revenue range), underpinning continual product refreshes across metrology, additive manufacturing, Raman spectroscopy and medical robotics.
- Hardware sales: one‑off capital equipment sales (CMM probes, spectrometers, machine tool probes, additive manufacturing systems, neurosurgical robots).
- Consumables & accessories: probe cartridges, calibration artefacts, spectroscopy consumables and service parts.
- Service & support: calibration, training, preventive maintenance contracts and retrofits - stable, high‑margin recurring income.
- Software & licensing: inspection software, process control and analytical software suites that add recurring or licence revenue streams.
| Metric | Latest reported year (FY) | Value (approx.) |
|---|---|---|
| Revenue | FY (latest reported) | £474.3m |
| R&D expenditure | FY (latest reported) | £63.7m (≈13% of revenue) |
| Employees | FY (latest reported) | ~4,600 |
| Manufacturing countries | Current | UK, Ireland, India, Brazil |
| R&D centres | Current | UK, Ireland, Slovenia |
- Manufacturing Technologies historically accounts for the majority of group revenue, driven by demand for metrology probes, gauging systems and machine tool integration in aerospace, automotive and precision engineering.
- Analytical Instruments & Medical Devices provides revenue diversification into life sciences, research and specialist healthcare; Raman spectroscopy and medical robotics are strategic growth areas.
- End‑market cyclicality: exposure to automotive and semiconductor cycles can create revenue variability; services and healthcare help smooth volatility.
- High engineering barriers to entry and strong IP portfolio (precision probes, calibration artefacts, spectroscopy algorithms, robotic control systems).
- Integrated product‑service model yielding recurring revenues and long customer lifecycles.
- Global footprint enabling OEM partnerships and regional support for complex capital equipment.
Renishaw plc (RSW.L): How It Works
Renishaw plc (RSW.L) operates as a precision engineering and manufacturing technology group whose products and services serve industrial metrology, additive manufacturing, and healthcare markets. The business model combines product sales, service contracts, software and training, and recurring consumables and support to generate diversified revenue streams.- Primary product families: coordinate measurement system probes and styli, gauging systems, additive manufacturing machines (e.g., RenAM series), and medical devices (neuromate® robot, neuroinfuse systems).
- Recurring revenue streams: software licenses, calibration and maintenance contracts, replacement probes/styli and consumables, and training/support services.
- Vertical focus: automotive, aerospace, electronics, industrial manufacturing, and healthcare providers (neurosurgery and drug delivery).
- Direct product sales - precision metrology hardware (CMM probes, Equator gauging systems) sold to OEMs and contract manufacturers.
- Medical devices and consumables - surgical robots (neuromate®), neuroinfuse drug delivery systems and related service/support sold to hospitals and specialist clinics.
- Additive manufacturing systems - sales of RenAM machines (e.g., RenAM 500 Ultra) plus powder, service and qualification programs for aerospace and high-value manufacturing.
- Software & digital services - measurement software, process control solutions, and integration services that increase customer lock-in and margin.
- Training & aftermarket support - paid courses, calibration, installation and long-term support contracts providing recurring income and higher lifetime customer value.
- High technical differentiation - precision, accuracy and IP in probe and metrology technology justify premium pricing.
- Aftermarket and consumables attached to installed base produce steady margins and recurring cash flow.
- Cross-selling between metrology, additive manufacturing and software in complex manufacturing accounts increases average deal size.
- Strategic cost reduction programs, operational efficiencies and supply-chain controls aimed at improving gross and operating margins.
| Metric | Value (approx.) |
|---|---|
| Annual revenue (latest full year) | £515m |
| Revenue split by business area | Metrology ~60% • Additive Manufacturing ~20% • Healthcare ~20% |
| R&D spend (annual) | ~£80m |
| Operating margin (approx.) | 10-15% |
| Net cash / (debt) | ~£200m (net cash position) |
| Installed base drivers | Thousands of metrology probes and multiple RenAM systems globally; growing consumer-electronics positioning for high-volume precision measurement |
- Sale of a RenAM 500 Ultra to an aerospace supplier: one-off machine revenue + recurring powder, service contracts, spare parts and software upgrades over the machine lifetime.
- Deployment of neuromate® in a hospital: device sale + training, maintenance contract and consumables for procedures.
- Equator gauging systems sold into consumer electronics: high-volume deployments paired with support and calibration services.
- Cost reduction and efficiency programs targeting manufacturing and supply-chain optimisation to protect margins during demand cycles.
- Investment in software, digital capabilities and service offerings to shift revenue toward higher-margin recurring streams.
- Targeted commercial expansion in consumer electronics and medical markets to diversify end-market exposure.
Renishaw plc (RSW.L): How It Makes Money
Renishaw plc (RSW.L) generates revenue primarily through precision metrology products and medical devices, with a strategic emphasis on innovation, diversification and sustainability to drive future growth.- Core revenue streams: touch-trigger and scanning probes for coordinate measuring machines (CMMs), additive manufacturing (metal 3D printing) systems, encoder and calibration systems, and medical devices (notably neurosurgical robotics and dental implants).
- Geographic mix: sales across Europe, North America, and APAC, with increasing exposure to high-growth APAC markets and industrial automation adopters.
- Competitive landscape: faces direct competition in metrology from Hexagon AB and Carl Zeiss AG; in medical devices and neurosurgical robotics competes with larger medtech firms such as Medtronic.
| Metric | Value / Note |
|---|---|
| CMM probe global revenue share (2024) | ~22% |
| Targeted long-term revenue growth | High single-digit % through the cycle |
| Targeted operating margin | Exceeding 20% |
| Key end-markets | Automotive, aerospace, medical, electronics, energy |
| Primary competitors | Hexagon AB, Carl Zeiss AG, Medtronic (medical) |
- How revenue is captured: product sales (hardware), service & support contracts, calibration and retrofitting services, consumables (probes, styli), and increasing recurring revenue from software and maintenance.
- Strategic levers for margin and growth: R&D-driven product differentiation, expansion of aftermarket services, operational efficiency and sustainability measures to reduce costs and appeal to ESG-conscious customers.
- Future outlook: positioned to capitalise on automation, Industry 4.0, and medical-robotics adoption-management aims to convert innovation and diversification into sustained high single-digit growth and operating margins above 20%.
Renishaw plc (RSW.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.